

BLIS M18™ Gains Australian Regulatory Approval

Blis Technologies has received notification from the Australian Therapeutic Goods Administration, that its probiotic strain *Streptococcus salivarius* BLIS M18 has been approved as an active ingredient for Listed Complementary Medicines.

CEO Brian Watson said, "This approval represents another important milestone for the company allowing us to progress plans for the launch of BLIS M18 based products in the Australian market with our distribution partner iNova Pharmaceuticals. iNova are in the early stages of launching the BLIS K12TM based product range in Australia which has had a positive response from the Pharmacy channel. We are excited about the opportunity to build on this positive momentum with a future BLIS M18 product launch"

For further information please contact: Brian Watson CEO Blis Technologies 027 7059133

About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and gum health. BLIS products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.

About iNova Pharmaceuticals

iNova Pharmaceuticals (iNova) is a multinational pharmaceutical and consumer health care company that markets and sells a wide range of market-leading products, primarily in the areas of weight management, cough & cold, throat, skin care and natural health. iNova operates in over 20 countries across Asia-Pacific and Africa. The iNova vision is to provide trusted brands that improve people's health and well-being every day. iNova is continually seeking innovative prescription medicines and consumer health care products through acquisition, licensing and co-marketing partnerships. iNova is ultimately owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group. More information about iNova can be found at www.inovapharma.com.